These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma. Peinemann F; Tushabe DA; van Dalen EC; Berthold F Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478 [TBL] [Abstract][Full Text] [Related]
3. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Pearson AD; Pinkerton CR; Lewis IJ; Imeson J; Ellershaw C; Machin D; ; Lancet Oncol; 2008 Mar; 9(3):247-56. PubMed ID: 18308250 [TBL] [Abstract][Full Text] [Related]
4. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival. Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410 [TBL] [Abstract][Full Text] [Related]
5. Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. Ladenstein R; Valteau-Couanet D; Brock P; Yaniv I; Castel V; Laureys G; Malis J; Papadakis V; Lacerda A; Ruud E; Kogner P; Garami M; Balwierz W; Schroeder H; Beck-Popovic M; Schreier G; Machin D; Pötschger U; Pearson A J Clin Oncol; 2010 Jul; 28(21):3516-24. PubMed ID: 20567002 [TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study. Rujkijyanont P; Photia A; Traivaree C; Monsereenusorn C; Anurathapan U; Seksarn P; Sosothikul D; Techavichit P; Sanpakit K; Phuakpet K; Wiangnon S; Chotsampancharoen T; Chainansamit SO; Kanjanapongkul S; Meekaewkunchorn A; Hongeng S BMC Cancer; 2019 Oct; 19(1):961. PubMed ID: 31619207 [TBL] [Abstract][Full Text] [Related]
7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
8. A nationwide phase II study of delayed local treatment for children with high-risk neuroblastoma: The Japan Children's Cancer Group Neuroblastoma Committee Trial JN-H-11. Yoneda A; Shichino H; Hishiki T; Matsumoto K; Ohira M; Kamijo T; Kuroda T; Soejima T; Nakazawa A; Takimoto T; Yokota I; Teramukai S; Takahashi H; Fukushima T; Hara J; Kaneko M; Ikeda H; Tajiri T; Mugishima H; Nakagawara A Pediatr Blood Cancer; 2024 Jun; 71(6):e30976. PubMed ID: 38577760 [TBL] [Abstract][Full Text] [Related]
9. OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age. Tweddle DA; Pinkerton CR; Lewis IJ; Ellershaw C; Cole M; Pearson AD Med Pediatr Oncol; 2001 Jan; 36(1):239-42. PubMed ID: 11464894 [TBL] [Abstract][Full Text] [Related]
10. Retinoic Acid for High-risk Neuroblastoma Patients after Autologous Stem Cell Transplantation - Cochrane Review. Peinemann F; van Dalen EC; Berthold F Klin Padiatr; 2016 Apr; 228(3):124-9. PubMed ID: 27011226 [TBL] [Abstract][Full Text] [Related]
11. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Hatlevoll R; Dahle R; Boye N; Wang M; Vigander T; Vilsvik J; Skovlund E; Hannisdal E; Aamdal S; J Clin Oncol; 2002 Dec; 20(24):4665-72. PubMed ID: 12488411 [TBL] [Abstract][Full Text] [Related]
12. Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: a Pediatric Oncology Group study. Castleberry RP; Cantor AB; Green AA; Joshi V; Berkow RL; Buchanan GR; Leventhal B; Mahoney DH; Smith EI; Hayes FA J Clin Oncol; 1994 Aug; 12(8):1616-20. PubMed ID: 8040674 [TBL] [Abstract][Full Text] [Related]
13. Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study. Amoroso L; Erminio G; Makin G; Pearson ADJ; Brock P; Valteau-Couanet D; Castel V; Pasquet M; Laureys G; Thomas C; Luksch R; Ladenstein R; Haupt R; Garaventa A; Cancer Res Treat; 2018 Jan; 50(1):148-155. PubMed ID: 28324923 [TBL] [Abstract][Full Text] [Related]
14. Role of chemotherapy resistance genes in outcome of neuroblastoma. de Cremoux P; Jourdan-Da-Silva N; Couturier J; Tran-Perennou C; Schleiermacher G; Fehlbaum P; Doz F; Mosseri V; Delattre O; Klijanienko J; Vielh P; Michon J Pediatr Blood Cancer; 2007 Mar; 48(3):311-7. PubMed ID: 16609945 [TBL] [Abstract][Full Text] [Related]
15. [Evaluation of efficacy of treatment for 30 children with neuroblastoma]. Sun XF; Liu DG; Su YS; Lin TY; Chen XQ; He YJ Ai Zheng; 2003 Dec; 22(12):1343-5. PubMed ID: 14693065 [TBL] [Abstract][Full Text] [Related]
16. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. Valteau-Couanet D; Michon J; Boneu A; Rodary C; Perel Y; Bergeron C; Rubie H; Coze C; Plantaz D; Bernard F; Chastagner P; Bouzy J; Hartmann O J Clin Oncol; 2005 Jan; 23(3):532-40. PubMed ID: 15659499 [TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen. Mastrangelo S; Rufini V; Ruggiero A; Di Giannatale A; Riccardi R Pediatr Blood Cancer; 2011 Jul; 56(7):1032-40. PubMed ID: 21344615 [TBL] [Abstract][Full Text] [Related]
18. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. Kushner BH; LaQuaglia MP; Bonilla MA; Lindsley K; Rosenfield N; Yeh S; Eddy J; Gerald WL; Heller G; Cheung NK J Clin Oncol; 1994 Dec; 12(12):2607-13. PubMed ID: 7527454 [TBL] [Abstract][Full Text] [Related]
19. Image-defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intra-operative risk factors and the completeness of resection. Irtan S; Brisse HJ; Minard-Colin V; Schleiermacher G; Galmiche-Rolland L; Le Cossec C; Elie C; Canale S; Michon J; Valteau-Couanet D; Sarnacki S Pediatr Blood Cancer; 2015 Sep; 62(9):1543-9. PubMed ID: 25820608 [TBL] [Abstract][Full Text] [Related]
20. Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial. Moreno L; Vaidya SJ; Schrey D; Pinkerton CR; Lewis IJ; Kearns PR; Machin D; Pearson ADJ; Pediatr Blood Cancer; 2019 Apr; 66(4):e27565. PubMed ID: 30516328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]